0001209191-23-032731.txt : 20230526
0001209191-23-032731.hdr.sgml : 20230526
20230526210035
ACCESSION NUMBER: 0001209191-23-032731
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230525
FILED AS OF DATE: 20230526
DATE AS OF CHANGE: 20230526
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tross Stuart A
CENTRAL INDEX KEY: 0001589641
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50865
FILM NUMBER: 23971167
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320-1799
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MANNKIND CORP
CENTRAL INDEX KEY: 0000899460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133607736
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CASPER STREET
CITY: DANBURY
STATE: CT
ZIP: 06810
BUSINESS PHONE: 818-661-5000
MAIL ADDRESS:
STREET 1: 1 CASPER STREET
CITY: DANBURY
STATE: CT
ZIP: 06810
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-25
0
0000899460
MANNKIND CORP
MNKD
0001589641
Tross Stuart A
1 CASPER STREET
DANBURY
CT
06810
0
1
0
0
Chief People & Workpl Officer
0
Common Stock, $.01 Par Value
2023-05-25
4
A
0
92000
0.00
A
1024752
D
Performance Restricted Stock Unit
2023-05-25
4
A
0
113000
0.00
A
Common Stock, $.01 Par Value
113000
113000
D
Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested.
The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
/s/ Stuart Tross
2023-05-26